特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
841563

喘息・慢性閉塞性肺疾患のFIC (ファーストインクラス) 新薬開発:喘息治療薬の開発がCOPDをリード

Asthma and Chronic Obstructive Pulmonary Disease: Asthma Ahead of COPD in Terms of Innovation with the Focus on Targeted Biologic Therapies for Severe Disease Phenotypes

出版日: | 発行: GlobalData | ページ情報: 英文 71 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.40円
喘息・慢性閉塞性肺疾患のFIC (ファーストインクラス) 新薬開発:喘息治療薬の開発がCOPDをリード
出版日: 2019年04月04日
発行: GlobalData
ページ情報: 英文 71 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

喘息および慢性閉塞性肺疾患 (COPD) においては、現在の標準的治療法が有効ではない重症喘息患者に向けた革新的治療薬、COPDの進行を逆転させる可能性のある治療薬に対し、アンメットニーズが残されています。

当レポートでは、喘息および慢性閉塞性肺疾患 (COPD) のFIC (ファーストインクラス) 新薬開発の動向を調査し、喘息・COPDの病因・病態生理、疫学、上市済み製品、喘息・COPD治療におけるアンメットニーズ、FICパイプラインの取り組み、主なパイプラインプログラムの状況などをまとめています。

第1章 目次

第2章 喘息・COPD:エグゼクティブサマリー

  • イノベーション:喘息から遅れをとるCOPD
  • 喘息パイプラインにおけるイノベーション:重篤な表現型を対象とした標的生物学的製剤への焦点
  • COPDパイプラインにおけるFICイノベーション:開発初期ステージに集中

第3章 イントロダクション

第4章 疾患概要

  • 病因・病態生理
  • 分類・病期
  • 持続的イノベーション
  • 疫学
  • 上市済み製品:概要

第5章 パイプライン製品イノベーションの評価

  • 概要
  • パイプライン:開発ステージ・分子タイプ別
  • パイプライン:分子標的別
  • パイプラインおよび市場におけるプログラムの比較分布:分子標的クラス別
  • FIC・非FICパイプラインプログラムの比較分布:分子標的クラス別
  • パイプライン中のFIC分子標的に対するFICプログラムの割合

第6章 FIC分子標的の評価

  • 概要
  • 喘息
  • COPD
  • 喘息・COPD

第7章 主要企業・契約

第8章 付録

図表

List of Tables

  • Table 1: Risk Factors for Asthma
  • Table 2: Risk Factors for COPD
  • Table 3: Classification of Asthma by Severity
  • Table 4: GOLD 2017 Assessment of Airflow Limitation in COPD
  • Table 5: GOLD 2017 Assessment of Symptoms/Risk of Exacerbations in COPD
  • Table 6: Asthma's Diagnosed Prevalent Cases (Millions), 2013-2023
  • Table 7: COPD's Diagnosed Prevalent Cases (Millions), 2015-2025

List of Figures

  • Figure 1: Global Asthma Market by Molecular Target and Molecule Type, 2019
  • Figure 2: Global COPD Market by Molecular Target and Molecule Type, 2019
  • Figure 3: Asthma, Global, Pipeline by Stage of Development and Molecule Type, 2019
  • Figure 4: COPD, Global, Pipeline by Stage of Development and Molecule Type, 2019
  • Figure 5: Asthma, Global, Pipeline by Molecular Target and Stage of Development, 2019
  • Figure 6: COPD, Global, Pipeline by Molecular Target and Stage of Development, 2019
  • Figure 7: Asthma, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2019
  • Figure 8: COPD, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2019
  • Figure 9: Asthma, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2019
  • Figure 10: Asthma, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2019
  • Figure 11: COPD, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2019
  • Figure 12: COPD, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2019
  • Figure 13: Asthma, Global, Ratio of First-in-Class and Non-First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019
  • Figure 14: COPD, Global, Ratio of First-in-Class and Non-First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019
目次
Product Code: GDHC492FP

In terms of First-in-Class (FIC) product innovation, the Chronic Obstructive Pulmonary Disease (COPD) pipeline is lagging behind the asthma pipeline. Higher levels of First-in-Class (FIC) innovation in the asthma pipeline are focused on meeting the large unmet need for therapies which can treat severe asthma phenotypes.

Asthma and Chronic Obstructive Pulmonary Disease (COPD) are both highly prevalent, chronic, inflammatory diseases of the airways and lungs. The asthma market is highly saturated with relatively efficacious standard therapies and the Chronic Obstructive Pulmonary Disease (COPD)market is also highly saturated with therapies that help to prevent exacerbations of the disease. However, there is considerable unmet need for innovative new therapies for severe asthmatics who do not respond to the current standards of care, and treatments which can reverse the progression of Chronic Obstructive Pulmonary Disease (COPD).

First-in-Class (FIC) product development in Chronic Obstructive Pulmonary Disease (COPD) constitutes only a small fraction of the pipeline. Of the pipeline products which had a disclosed molecular target, only 31% are FIC products. In contrast, 41% of the asthma pipeline with a disclosed molecular target is a FIC product. Further to this, 66% of the First-in-Class (FIC) products in the Chronic Obstructive Pulmonary Disease (COPD) pipeline are found in the preclinical stage of development with no First-in-Class (FIC) products in Phase III development or later.

The industry average for First-in-Class (FIC) innovation within a disease area is approximately 40%, which means that not only is innovation in the Chronic Obstructive Pulmonary Disease (COPD) pipeline relatively low in comparison to the asthma pipeline, it is also much lower than the industry average. Combined with the lack of late-stage innovation, it is unlikely that any FIC products will be entering the Chronic Obstructive Pulmonary Disease (COPD) market in the near future.

There is a high unmet need for therapies that treat severe asthma and this is reflected in the asthma pipeline. Monoclonal antibodies (mAbs) are the second most common molecule type in the asthma pipeline, indicating high levels of interest in developing targeted biologic therapies for severe phenotypes of asthma. The asthma market is saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs) and inhaled corticosteroids (ICSs). Therefore, the development of targeted biologic therapies for severe phenotypes of asthma is one way that companies can penetrate the asthma market.

The most prevalent molecular target class in the asthma pipeline is cytokines/chemokines and their receptors, which account for 18% of the pipeline. This group itself is diverse, although interleukins (ILs) and IL receptors are by far the most numerous targets among the cytokines, with IL-33, IL-4, IL-5 and IL-17 being targeted most frequently. These ILs are heavily implicated in the inflammatory response, notably for their role in recruiting inflammatory cells such as eosinophils. The specificity of these therapies means they are highly effective in specific, more severe sub-types of asthma patients, such as those characterized by elevated levels of eosinophils.

The report "Asthma and Chronic Obstructive Pulmonary Disease: Asthma Ahead of COPD in Terms of Innovation with the Focus on Targeted Biologic Therapies for Severe Disease Phenotypes", assesses First-in-Class (FIC) innovation across the asthma and Chronic Obstructive Pulmonary Disease (COPD) pipelines.

Scope

  • Both the asthma and COPD markets are highly saturated. Which drug classes are used to treat these disorders? How do the drug classes in the market compare with those in the pipelines?
  • There are 266 and 161 pipeline programs in active development for asthma and COPD, respectively. What proportion of these products are first-in-class? How does first-in-class innovation vary by indication, development stage and molecular target class?
  • Which molecular target classes are prominently represented in the first-in-class asthma and COPD pipelines? Which first-in-class targets have been identified as most promising for asthma and COPD, and is there any overlap?
  • Which companies are the key players within the asthma and COPD markets? Who has been involved in the most licensing and co-development deals for asthma and COPD products? Which first-in-class products have prior deal involvement?

Reasons to buy

  • Understand the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems, epidemiology, and treatment options for both asthma and COPD.
  • Visualize the composition of the asthma and COPD markets in terms of dominant molecule types and molecular targets. This allows an understanding of any gaps in the current market.
  • Analyze and compare the asthma and COPD pipelines and stratify by stage of development, molecule type, and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products for each indication have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.
  • Recognize commercial opportunities by identifying first-in-class asthma and COPD pipeline products that have not yet been involved in licensing or co-development deals, and by analyzing company strategies in prior deals through case studies of key deals for asthma and COPD first-in-class products.

Table of Contents

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Asthma and COPD: Executive Summary

  • 2.1 COPD Lagging Behind Asthma in Terms of Innovation
  • 2.2 Innovation in Asthma Pipeline is Focused Towards Targeted Biologic Therapies for Severe Phenotypes of the Disease
  • 2.3 FIC Innovation in COPD Pipeline is Concentrated at the Early Development Stages

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
  • 4.2 Classification or Staging Systems
  • 4.3 Sustained Innovation in Asthma and COPD
  • 4.4 Epidemiology for Asthma and COPD
  • 4.5 Overview for Marketed Products

5 Assessment of Pipeline Product Innovation

  • 5.1 Overview
  • 5.2 Pipeline by Stage of Development and Molecule Type
  • 5.3 Pipeline by Molecular Target
  • 5.4 Comparative Distribution of Programs Between the Market and Pipeline by Molecular Target Class
  • 5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
  • 5.6 Ratio of First-in-Class Programs to First-in-Class Molecular Target within the Pipeline

6 First-in-Class Molecular Target Evaluation

  • 6.1 Overview
  • 6.2 Asthma
  • 6.3 COPD
  • 6.4 Asthma and COPD

7 Key Players and Deals

  • 7.1 Overview

8 Appendix

  • 8.1 Bibliography
  • 8.2 Abbreviations
  • 8.3 Methodology
  • 8.4 About the Authors
  • 8.5 About GlobalData
  • 8.6 Contact Us
  • 8.7 Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.